TrialBlood2021

A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.

Alison J Moskowitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.